Skip to Content

'
Michael A Davies, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
7455 Fannin Street
Unit Number: 904
Houston, TX 77054
Room Number: SCR2.3019
Email: MDavies@mdanderson.org

Education & Training

Degree-Granting Education

2001 The University of Texas Health Science Center, Houston, TX, MD, PhD, Molecular Biology
1993 The University of Texas at Austin, Austin, TX, BA, Liberal Arts

Postgraduate Training

7/2004-6/2007 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/2001-6/2004 Clinical Residency, Internal Medicine, Massachusetts General Hospital, Boston, MA

Board Certifications

11/2007 Medical Oncology
8/2004 American Board of Internal Medicine

Professional Memberships

American Association for Cancer Research
Member, 2008-present
American Society of Clinical Oncology
Member, 2004-present
Harris County Medical Association, Houston, TX
Member, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Frederick DT, Salas Fragomeni RA, Schalk A, Neira IF, Hoff T, Cooper ZA, Haq R Panka DJ, Kwong LN, Davies MA, Cusack JC, Flarherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale. PLOS One 9(7), 7/2014. PMCID: PMC4077767.
2. Chen G, Davies MA. Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma. Hematology/Oncology Clinics of North America 28(3):523-536, 6/2014. PMID: 24880945.
3. Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y. A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget 5(10):2912-7, 5/2014. PMID: 24913145.
4. Davies MA. Finding the Right Balance of BRAF Inhibition in Melanoma. Cancer Discov 4(5):510-2, 5/2014. PMID: 24795008.
5. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff M, Wubberhorst B, Kim SB, Kopetz S, Ledoux A, Yennu Nanda VG, Goncalves Pereira C, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA. Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clin Cancer Res. e-Pub 5/2014. PMID: 24803579.
6. Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. Oncotarget. e-Pub 4/2014. PMID: 24743024.
7. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma. Melanoma Res. e-Pub 4/2014. PMID: 24743052.
8. Glitza IC, Davies MA. Genotyping of Cutaneous Melanoma. Chinese Clinical Oncology, 3/2014.
9. Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK. Targeting ER stress induced-autophagy overcomes resistance to BRAF inhibition in melanoma. J Clin Invest 124(3):1406-17, 3/2014. e-Pub 2/2014. PMCID: PMC3934165.
10. Turley RS, Tokuhisa Y, Toshimitsu H, Lidsky ME, Padussis JC, Fontanella A, Deng W, Augustine CK, Beasley GM, Davies MA, Dewhirst MW, Tyler DS. Targeting N-cadherin Increases Vascular Permeability and Differentially Activates AKT in Melanoma. Ann Surg. e-Pub 3/2014. PMID: 24646553.
11. Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso JA, Sikora AG. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res 74(4):1067-87, 2/2014. e-Pub 1/2014. PMID: 24398473.
12. Curry JL, Davies MA, Calderone TL, Nathanson K, Prieto VG, Gershenwald JE. Tissue resources for clinical use and marker studies in melanoma. Methods Mol Biol 1102:679-95, 2014. PMID: 24259006.
13. Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119(21):3821-9, 11/2013. e-Pub 8/2013. PMID: 23922205.
14. Prickett TD, Zerlanko B, Gartner JJ, Parker SC, Dutton-Regester K, Lin JC, Teer JK, Wei X, Jiang J, NISC Comparative Sequencing Program, Chen G, Davies MA, Gershenwald JE, Robinson W, Robinson S, Hayward NK, Rosenberg SA, Margulies EH, Samuels Y. Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. J Invest Dermatol. e-Pub 9/2013. PMID: 24008424.
15. Nathanson KL, Martin AM, Wubbenhorst B, Greshock J, Letrero R, D'Andrea K, O'Day S, Infante JR, Falchook GS, Arkenau HT, Millward M, Brown MP, Pavlick A, Davies MA, Ma B, Gagnon R, Curtis CM, Lebowitz PF, Kefford RF, Long GV. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF ihibitor Dabrafenib (GSK2118436). Clin Cancer Res 19(17):4868-78, 9/2013. e-Pub 7/2013. PMID: 23833299.
16. Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, Davis S, Simhadri VL, Jha S, Katagiri N, Gotea V, Teer JK, Wei X, Morken MA, Bhanot UK, NISC Comparative Sequencing Program, Chen G, Elnitski LL, Davies MA, Gershenwald JE, Carter H, Karchin R, Robinson W, Robinson S, Rosenberg SA, Collins FS, Parmigiani G, Komar AA, Kimchi-Sarfaty C, Hayward NK, Margulies EH, Samuels Y. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A 110(33):13481-6, 8/2013. e-Pub 7/2013. PMID: 23901115.
17. Overman MJ, Zhang J, Kopetz S, Davies MA, Jiang Z, Stemke-Hale K, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H. Gene expression profiling of amupllary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLOS One 8(6), e65144, 6/2013. PMCID: PMC3679143.
18. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R. Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. J Mol Diagn 15(2):220-6, 3/2013. e-Pub 12/2012. PMID: 23273605.
19. Patel SP, Lazar AJ, Papadopoulos NE, Liu P, Infante JR, Glass MR, Vaughn CS, Lorusso PM, Cohen RB, Davies MA, Kim KB. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer 119(4):799-805, 2/2013. e-Pub 9/2012. PMID: 22972589.
20. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. Clin Cancer Res 19(3):657-667, 2/2013. e-Pub 12/2012. PMCID: PMC3563727.
21. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Frederick DT, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Anti-tumor Activity of Adoptive Immunotherapy in Mice. Clin Cancer Res 19(2):393-403, 1/2013. e-Pub 11/2012. PMID: 23204132.
22. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 15, 12/2012. e-Pub 10/2012. PMID: 23032743.
23. Beasley GM, Coleman AP, Raymond A, Sanders G, Selim MA, Peterson BL, Brady MS, Davies MA, Augustine C, Tyler DS. A phase I multi-institutional sudy of systemic sorafenib in conjunction wiht regional melphalan for in-transit melanoma of the extremity. Ann Surg Oncol 19(12):3896-905, 11/2012. e-Pub 5/2012. PMID: 22549288.
24. Joseph RW, Eckel-Passow JE, Sharma R, Liu P, Parker A, Jakob J, Buchbinder E, Bassett RL, Davies MA, Hwu P, Atkins MB, Sullivan RJ. Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. J Immunother 35(9):711-715, 11/2012. PMID: 23090080.
25. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087-95, 11/2012. e-Pub 10/2012. PMID: 23051966.
26. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clin Cancer Res 18(19):5329-40, 10/2012. e-Pub 7/2012. PMCID: PMC3463754.
27. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 39(9):821-5, 9/2012. e-Pub 7/2012. PMID: 22809251.
28. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. Combination small molecule MEK and P13K inhibition enhances uveal melanoma cell death in a mutant GNAQ and GNA11 dependant manner. Clin Cancer Res 18(16):4345-55, 8/2012. e-Pub 6/2012. PMID: 22733540.
29. Alvarado G, Noor R, Basset R, Papadopoulos NE Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 22(4):310-5, 8/2012. PMID: 22584956.
30. Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of activated c-Met with NRAS-mutated human melanomas: A possible avenue for targeting. Int J Cancer 131(2):E56-65, http://onlinelibrary.wiley.com/doi/10.1002/ijc.26487/abstract;jsessionid=8C962BAF95B31E3A7308AD99279BC1B1.d01t03, 7/2012. e-Pub 1/2012. PMCID: PMC3337366.
31. Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer 131(1):8-17, 7/2012. e-Pub 7/2011. PMID: 21792892.
32. Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA. Correlation of NRAS mutations with clinical response to high dose IL-2 in patients with advanced melanoma. J Immunother 35(1):66-72, 1/2012. PMCID: PMCPMC3241890.
33. Bedikian AY, Silverman JA, Papodopolous NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies MA, Hwu P. Pharmacokinetics and Safety of Marqibo (Vincristine Sulfate Liposomes Injection) in Cancer Patients with Impaired Liver Function. J Clin Pharmacol 51(8):1205-12, 8/2011. PMID: 20978276.
34. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. Cancer - Am Cancer Soc 117(8):1687-96, 4/2011. e-Pub 10/2010. PMID: 20960525.
35. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70(21):8736-8747, 11/2010. e-Pub 10/2010. PMID: 20959481.
36. Altman MK, Gopal V, Jia W, Yu S, Hall H, Mills GB, McGinnis AC, Bartlett MG, Jiang G, Madan D, Prestwich GD, Xu Y, Davies MA, Murph MM. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer 9:140, 6/2010. PMCID: PMC2895597.
37. Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, Mills GB. Physical Association of PDK1 with AKT1 is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase. PLoS One 5(3):e9910, 3/2010. PMCID: PMC2845649.
38. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res 16(6):1834-44, 3/2010. e-Pub 3/2010. PMCID: PMC2858983.
39. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9(2):257-67, 2/2010. e-Pub 2/2010. PMID: 20124458.
40. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15(24):7538-7546, 12/2009. PMID: 19996208.
41. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, Davies MA, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 22(11):1446-56, 11/2009. e-Pub 8/2009. PMID: 19718013.
42. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Vashisht Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of Dasatinib Against L576P KIT Mutant Melanoma: Molecular, Cellular, and Clinical Correlates. Mol Cancer Ther 8(8):2079-85, 8/2009. e-Pub 8/2009. PMID: 19671763.
43. Vasudevan KM*, Barbie DA*, Davies MA*, Rabinovsky R, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, McNear CJ, Sandy P, Hoesch S, Sheng Q, Gupta P, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA (*contributed equally). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer *Featured on Cover. Cancer Cell 16(1):21-32, 7/2009. PMID: 19573809.
44. Aziz SA, Davies MA, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res 15(9):3029-36, 5/2009. e-Pub 4/2009. PMID: 19383818.
45. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. Brit J Cancer 99(8):1265-1268, 9/2008. PMID: 18813315.
46. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies MA, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. Cancer Res 68(15):6084-91, 8/2008. PMID: 18676830.
47. Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 21(15):2357-2364, 2002. PMID: 11948419.
48. Koul D, Parthasarathy R, Shen R, Davies MA, Jasser SA, Chintala SK, Rao JS, Sun Y, Benvenisite EN, Liu TJ, Yung WK. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20(46):6669-78, 10/2001. PMID: 11709701.
49. Beresford SA, Davies MA, Gallick GE, Donato NJ. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells. J Interferon Cytokine Res 21(5):313-22, 5/2001. PMID: 11429162.
50. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 19(47):5406-5412, 2000. PMID: 11103942.
51. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18(50):7034-45, 11/1999. PMID: 10597304.
52. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59(11):2551-6, 6/1999. PMID: 10363971.
53. Delehedde M, Cho SH, Sarkiss M, Brisbay S, Davies MA, El-Naggar AK, McDonnell TJ. Altered expression of bcl-2 family member proteins in nonmelanoma skin cancer. Cancer 85(7):1514-22, 4/1999. PMID: 10193941.
54. Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58(23):5285-90, 12/1998. PMID: 9850049.

Invited Articles

1. Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol 87(3):381-9, 2/2014. e-Pub 11/2013. PMID: 24291778.
2. Davies MA. Targeted Therapy for Cutaneous Melanoma: Beyond. J Patient-Centered Res Rev. 1(1):12-20, 2014.
3. Kwong LN, Davies MA. Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma. Clin Cancer Res 19(19):5310-9, 10/2013. PMCID: PMC3811159.
4. Kwong LN, Davies MA. Targeted Therapy for Melanoma: Rational Combinatorial Approaches. Oncogene, 2/2013. e-Pub 2/2013. PMID: 23416974.
5. Davies MA. The Role of the P13K-AKT Pathway in Melanoma. Cancer J 18(2):142-7, 3/2012. PMID: 22453015.
6. Woodman SE, Davies MA. Targeting KIT in Melanoma: A Paradigm of Molecular Medicine and Targeted Therapeutics. Biochem Pharmacol 80(5):568-74, 9/2010. e-Pub 5/2010. PMID: 20457136.
7. Davies MA, Hennessy B, Mills GB. Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmaco 16(16):2243-61, 11/2006. PMID: 17059381.
8. Davies MA. Metastatic renal cell carcinoma: new standards for first-line therapy? Molecular Oncology Report, 2006.
9. Kwng LN, Davies MA. Activation and Targeting of teh P13-K-AKT Pathway in Melanoma. Clinical Cancer Research. Submitted.

Abstracts

1. Davies MA, Tawbi H, Ouellet D, Lazar AJF, Weinberg JS, Butterfiels LH, Hamilton RL, Amankulor N, Engh JA, Shivlingham B, Kefford R, Scoyer GV, Mahmood S, Richards-Peterson LE, Swann S, Arbushites MC, Long GV, Kirkwood JM. Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation–positive melanoma with metastases to the brain (BRV116521). ASCO Annual Meeting 2014 (#TPS9112), 2014.
2. Davies MA, Martins KD, Sessa T, Swann S. Phase II, open-label study of dabrafenib plus trametinib in patients with BRAF mutation-positive melanoma brain metastases: A GSK-sponsored trial. ASCO Annual Meeting 2014 (#TPS9106), 2014.
3. Glitza IC, Bernatchez C, Bassett RL, Vaughn C, Velasquez P, Diab A, Amaria RN, Yee C, Woodman SE, Patel SP, Kim KB, Davies MA, Papadopoulos NE, Bedikian AY, Hwu WJ, Radvanyi LG, Hwu P. Treatment with tumor-infiltrating lymphocytes (TIL) in metastatic melanoma and clinical benefit regardless of site of origin, mutation status, or prior checkpoint blockade. ASCO Annual Meeting 2014 (#9079), 2014.
4. Yorio JT, Bucheit AD, McIntyre S, Fox P, Bassett R, Davies MA. Toxicities and outcomes in metastatic melanoma patients (pts) treated with Ipilimumab (Ipi) and BRAF inhibitors (BRAFi). Society for Melanoma Research Meeting, 11/2013.
5. Stockman D, Tetzlaff MT, Al-Zaid T, Torres-Cabala CA, Bucheit AD, Lazar AJF, Sui D, Jakob JA, Bassett R, Prieto VG, Davies MA, Curry JL. Differential clinical associations of BRAF and NRAS mutations among histologic types of cutaneous melanomas. ASCO Annual Meeting 2013 31, 2013.
6. Bucheit AD, Joseph RW, Milton D, Fox P, BAssett R, Gershenwald JE, Tetzlaff MT, Prieto VG, Lazar AJ, Davies MA. PTEN loss correlates with shorter time to brain metastasis and overall survival in stage IIIB/C melanoma patients. 2013 ESMO, 2013.
7. Chen G, Kim SB, Lazar AJ, Stemke-Hale K, Deng W, Lee JS, Davies MA. Characterization of point mutations and copy number changes in melanoma patients with matched brain and extracranial metastases. 2012 SMR Congress, 11/2012.
8. Yennu Nanda VG, Komurov K, Patel LR, Chen G, Ram PT, Guichard S, Smith PD, Davies MA. The dual MTOR inhibitor AZD8055 synergizes with MEK inhibition in a metabolically unique subset of MEK inhibitor-resistant melanomas. 2012 SMR Congress, 11/2012.
9. Kirkwood JM, Long GV, Trefzer, Davies MA, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Kefford R, Goodman VL, Switzky JC, Swann RS, Martin AM, Guckert ME, Streit MRW, Schandendorf D. BREAK-MB: a Phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600 E/K mutation-positive melanoma with brain metastases (mets). ASCO Annual Meeting 2012, 6/2012.
10. Koay EJ, Bucheit AD, Jakob JA, Hyun ED, Settle SH, Brown PD, Davies MA, Sulman EP,. Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma patients with brain metastasis. ASCO Annual Meeting 2012, 6/2012.
11. Mu H, Calderone TL, Davies MA, Prieto V, Wang H, Mills GB, Bar-Eli M, Gershenwald JE. Lysophosphatidic Acid Induces Lymphangiogenesis and Interleukin-8 Production in Human Lymphatic Endothelial Cells. Am J Pathol 180(5):2170-81 (#80763), 5/2012. e-Pub 3/2012. PMID: 22465753.
12. Davies MA. Molecular and clinical correlates of PTEN expression in melanoma. AACR Annual Meeting 2012 (#5003), 4/2012.
13. Joseph RW, Hwu P, Davies MA, Atkins MB, Sullivan RJ. Clinical benefit of ipilmumab in patients with metastatic melanoma who progress on high dose IL-2. 2011 ASCO Annual Meeting (#79429), 6/2011.
14. Jakob JA, Bassett RL, Ng CS, Lazar AJF, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Hwu P, Kim KB, Davies MA. Clinical characteristics and otucomes associated with BRAF and NRAS mutations in metastatic melanoma. 2011 ASCO Annual Meeting (#76931), 6/2011.
15. Patel SP, Bedikian AY, Papadopoulos NE, Hwu WJ, Kim KB, Homsi J, Davies MA, Woodman SE, Radvanyi LG, Woodard K, Mahoney S, Hwu P. Ipilmumab plus temozolomide in metastatic melanoma. 2011 ASCO Annual Meeting (#83677), 6/2011.
16. Pravinkumar SE, Nigam R, Hwu P, Davies MA, Price K. Intensive care unit resource utilization for high dose interleukin-2 therapy: A 3-year experience from a large oncologic ICU. 2011 Canadian Respiratory Conference, 4/2011.
17. Joseph RW, Sullivan RJ, Panka D, Manoukian G, Percy A, Harrell R, Bassett RL, Atkins MB, Hwu P, Davies MA. Effect of mutational status on response, PFS, or OS after the treatment with IL-2 for metastatic melanoma. 2010 ASCO Annual Meeting (#8597), 6/2010.
18. Davies MA, Gershenwald JE. Integrated Analysis of Kinase Signaling Pathways in Melanoma Clinical Specimens. 2009 NCI Translational Meeting, 11/2009.
19. Davies MA, Lee JS. Integrated Analysis of Phospho-Proteins and Gene Expression Profiles Identifies P-GSK3 as a Critical Node in Melanoma. 2009 S.M.R. International Congress Meeting, 11/2009.
20. Kim KB, Davies MA, Papadopoulos NE, Bedikian AY, Hwu W, Woodard K, Washington EW, Dancey JE, Wright J, Hwu P. Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. ASCO Annual Meeting (#9026), 5/2009.
21. Davies MA, Stemke-Hale K, Calderone T, Deng W, Lazar A, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Quantitative assessment of AKT activation in melanoma. ASCO Annual Meeting (#9022), 5/2009.
22. Woodman SE, Trent JC, Stemke-Hale K, Lazar A, Pricl S, Pavan GM, Papadopoulos N, Hwu P, Mills GB, Davies MA. Selective Activity of Dasatinib for the Most Common KIT Mutation in Melanoma (L576P). ASCO Annual Meeting, 5/2009.
23. *Vasudevan KM, *Barbie DA, *Davies MA, Rabinovsky R, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, McNear CJ, Kim J, Boehm JS, Silver S, Lu Y, Stemke-Hale K, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. PDK1-SGK3 signaling in the absence of AKT activation in PIK3CA-mutant cancers. 2009 AACR Annual Meeting (#3822), 4/2009.
24. Yordy JS, Byers LA, Davies MA, Mills G, Ju Z, Ang KK, Heymach JV. Protein Expression Profiling Identifies Markers of Radiation Sensitivity and Resistance in the NCI 60 Cell Lines. ASCO-NCI-EORTC Annual Meeting, 11/2008.
25. Yordy JS, Byers LA, Davies MA, Molkentine D, Raju U, Mills G, Minna J, Coombes K, Ang KK, Heymach JV. Reverse Phase Protein Arrays Reveal Biomarkers of Radiation Resistance in Head & Neck and Lung Cancer Cell Lines. Translational Advances in Radiation Oncology and Cancer Imaging Symposium, 10/2008.
26. Davies MA, Vasudevan KM, Hennessy BT, Rabinovsky R, Stemke-Hale K, Tseng H, Dutta B, Garraway LA, Mills GB. AKT-independent, PDK1-dependent signaling by oncogenic PIK3CA mutations. AACR Translational Cancer Medicine (#A44), 7/2008.
27. Hwu WJ, Ivan D, Prieto VG, Simon J, Jones D, Ekmekcioglu S, Davies MA, Ayala AE, Garcia ME, Ross M. Randomized phase II neoadjuvant study of temozolomide (TMZ) alone or with pegylated interferon-alfa 2b (PGI) in patients with resectable AJCC stage IIIC or stage IV (M1a) metastatic melanoma. ASCO Annual Meeting (#20024), 5/2008.
28. Kopetz ES, Wu J, Davies MA, Parikh N, Johnson F, Gallick G, and Donato N. Synergistic activity of Src and EGFR inhibitors in colon cancer. AACR Annual Meeting (#4079), 4/2007.
29. Kopetz S, Wu J, Davies MA, Johnson F, and Donato N. Synergistic effects of combination therapy with anti-EGFR and anti-Src therapy in vitro in colon cancer. ASCO Gastrointestinal Cancers Symposium (#406), 2007.
30. Davies MA, Bedikian AY, McIntyre S, Smith T, Kim K, Hwu W, Papadopoulos N, and Hwu P. Natural history of melanoma patients with CNS metastases. ASCO Annual Meeting (#8054), 2006.

Book Chapters

1. Davies MA, Garraway LA. Molecularo Biology of Cutaneousl Melanoma. In: 10th Edition of Cancer: Principles & Practices of Oncology. Lippincott Williams & Wilkins, 2014.
2. Kupferman ME, Davies MA. Melanoma of the Head and Neck: General Principles and Management. In: Head and Neck Cancer A Multidisciplinary Approach, 4th. Wolters Kluwer Lippincott Williams & Wilkins, 672-691, 2013. ISBN: 978-1-45114487-1.
3. Kim KB, Davies MA, Rapini RP, Hwu P, Bedikian AY. Malignant Melanoma. In: The MD Anderson Manual of Medical Oncology, Second Edition, 2nd. McGraw Hill: China, 1077-1109, 2011.
4. Ahmed KB, Davies MA. New Molecular Targets for Systemic Therapy of Melanoma. In: Research on Melanoma - A Glimpse into Current Directions and Future Trends,. Ed(s) M Murph. InTech - Open Access Publisher, 161-180, 2011. ISBN: 978-953-307-293-7.
5. Davies MA, Patel S, Kim K. Targeted Therapy in Melanoma. In: Targeted Therapy in Cancer, 1. Ed(s) Kurzrock R, Markman M. Humana Press: Totowa, NJ, 183-211, 2008. ISBN: 978-1-60327-423-4.
6. Davies MA. PTEN, a tumor suppressor gene frequently mutated in glioblastomas. In: Genomic and Molecular Neuro-Oncology. Ed(s) Wei Zhang and Gregory N. Fuller. Jones and Bartlett: Sudbury, MA, 47-61, 2004.

Last updated: 7/15/2014